DE602006019710D1 - Magnesiumsalze von hmg-coa-reduktase-hemmern - Google Patents

Magnesiumsalze von hmg-coa-reduktase-hemmern

Info

Publication number
DE602006019710D1
DE602006019710D1 DE602006019710T DE602006019710T DE602006019710D1 DE 602006019710 D1 DE602006019710 D1 DE 602006019710D1 DE 602006019710 T DE602006019710 T DE 602006019710T DE 602006019710 T DE602006019710 T DE 602006019710T DE 602006019710 D1 DE602006019710 D1 DE 602006019710D1
Authority
DE
Germany
Prior art keywords
coa reductase
magnesium salt
reductase inhibitors
hmg coa
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019710T
Other languages
English (en)
Inventor
Yatendra Kumar
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006019710(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of DE602006019710D1 publication Critical patent/DE602006019710D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DE602006019710T 2005-05-03 2006-05-03 Magnesiumsalze von hmg-coa-reduktase-hemmern Active DE602006019710D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108DE2005 2005-05-03
PCT/IB2006/051396 WO2006117761A2 (en) 2005-05-03 2006-05-03 Magnesium salts of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
DE602006019710D1 true DE602006019710D1 (de) 2011-03-03

Family

ID=37308379

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019710T Active DE602006019710D1 (de) 2005-05-03 2006-05-03 Magnesiumsalze von hmg-coa-reduktase-hemmern

Country Status (9)

Country Link
US (1) US20100222405A1 (de)
EP (2) EP2172452A1 (de)
AT (1) ATE496025T1 (de)
DE (1) DE602006019710D1 (de)
DK (1) DK1879862T3 (de)
ES (1) ES2304911T3 (de)
NO (1) NO20076191L (de)
PT (1) PT1879862E (de)
WO (1) WO2006117761A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
CA2631549A1 (en) * 2005-11-29 2007-06-07 Biocon Limited Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
IS8587A (is) * 2006-12-27 2008-06-28 Actavis Group Hf. Atorvastatin lyfjasamsetning
WO2009063476A1 (en) * 2007-11-16 2009-05-22 Biocon Limited A crystalline form of atorvastatin hemi magnesium salt and a process thereof
EP2130819A3 (de) 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Kristalline Formen von Atorvastatin-Magnesium
WO2009157005A1 (en) * 2008-06-26 2009-12-30 Biocon Limited Crystalline forms of atorvastatin hemi-magnesium salt and a process thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
AP2004003112A0 (en) 2002-02-14 2004-09-30 Ranbaxy Lab Ltd Formulations of atorvastatin stabilised with alkali metal additions
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1833466A1 (de) * 2004-12-28 2007-09-19 Ranbaxy Laboratories Limited Verfahren zur herstelulng von stabilen pharmazeutischen soliden dosierformen von atorvastatin und amlodipin
MX2007009281A (es) * 2005-02-10 2007-09-25 Lufecycle Pharma As Composicion farmaceutica estable que comprende una combinacion de dosis fija de fenofibrato y un inhibidor de 3-hidroxi 3-metilglutaril-coenzima a reductasa.
PT1957452E (pt) * 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
CA2631549A1 (en) * 2005-11-29 2007-06-07 Biocon Limited Polymorphs of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l-heptanoic acid magnesium salt (2: 1)
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
EP2016048A4 (de) * 2006-05-11 2010-06-23 Biocon Ltd Kristalline form b4 von atorvastatin-magnesium und verfahren dafür
EP2130819A3 (de) * 2008-04-10 2009-12-23 Ranbaxy Laboratories Limited Kristalline Formen von Atorvastatin-Magnesium

Also Published As

Publication number Publication date
ES2304911T3 (es) 2011-05-30
EP1879862A2 (de) 2008-01-23
WO2006117761A2 (en) 2006-11-09
ES2304911T1 (es) 2008-11-01
NO20076191L (no) 2008-01-30
EP2172452A1 (de) 2010-04-07
PT1879862E (pt) 2011-04-19
US20100222405A1 (en) 2010-09-02
DK1879862T3 (da) 2011-05-16
EP1879862B1 (de) 2011-01-19
WO2006117761A3 (en) 2007-03-29
ATE496025T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
SG166829A1 (en) Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA201270546A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EA201691142A1 (ru) Ингибиторы мек и способы их применения
WO2007026920A3 (en) Amide derivatives as rock inhibitors
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA200801199A1 (ru) Ингибиторы киназы
EA200601608A1 (ru) Способ производства твёрдой фармацевтической композиции
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2008062476A3 (en) Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
MX2009003981A (es) Agentes moduladores del receptor de calcio.
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TNSN05306A1 (en) Substituted pyrrole derivatives.
EA200601678A1 (ru) Новые имидазолы
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
NO20043919L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
GR1006879B (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar